Zobrazeno 1 - 10
of 435
pro vyhledávání: ''
Autor:
C. Meyer, Y. Fouché, Emmanuel Chamorey, M. Dejode, C. Bailleux, J. Haudebourg, Renaud Schiappa, Y. Delpech, Emmanuel Barranger
Publikováno v:
Clinical Breast Cancer. 22:121-126
Background Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of this retrospective study was to identify factors delaying initiation of adjuv
Autor:
Fei Ma, Yanxia Sun, Qing Li, Peng Yuan, Shanshan Chen, Jiayu Wang, Yang Luo, Ying Fan, Pei Yu, Binghe Xu, Yiqun Han, Ruigang Cai, Qiao Li, Pin Zhang
Publikováno v:
Clinical Breast Cancer. 21:e497-e505
Different clinicopathologic characteristics could contribute to inconsistent prognoses of small breast neoplasms (T1a/T1b). This study was done to conduct a retrospective analysis and establish a clinical prediction model to predict individual surviv
Autor:
Nicole Rademacher, Tina W.F. Yen, Kirsten M. M. Beyer, Sara Beltrán Ponce, Purushottam W. Laud, Emily L. McGinley, Ann B. Nattinger, Sima Namin, Jamila L. Kwarteng, Courtney Jankowski, Yuhong Zhou
Publikováno v:
Journal of Clinical Oncology. 39:2749-2757
PURPOSE The objective was to examine the relationship between contemporary redlining (mortgage lending bias on the basis of property location) and survival among older women with breast cancer in the United States. METHODS A redlining index using Hom
Autor:
Qianxue Wu, Hongyuan Li, Qing Li, Wenming Zhu, Zhuyue Li, Xiang Zhang, Kang Wang, Ling Yang, Yang Shi
Publikováno v:
Clinical Breast Cancer. 21:360-372
Purpose: Although patients diagnosed with ductal carcinoma in situ (DCIS) harbor excellent overall survival after breast conserving therapy, the evidence regarding to surgical management for ipsilateral breast tumor recurrence (IBTR) is scarce. This
Autor:
Abdurrahman Aldiab, Ammar C. Al-Rikabi, Khalid Alsaleh, Nashwa Abd El-Aziz, Tareq Salah, Sufia Husain, Maria Arafah
Publikováno v:
Clinical Breast Cancer. 21:e362-e367
Progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) significantly influence disease prognosis and therapeutic response in patients with breast cancer. Neoadjuvant chemotherapy (NACT) can change the
Publikováno v:
Clinical Breast Cancer. 21:e471-e478
Male breast cancer (MBC) comprises1% of all cancers and continues to rise. Because of rarity, there is paucity in the literature; therefore, management of MBC is generalized from female breast cancer (FBC).Data from 152 VA Medical Centers were used t
Publikováno v:
Future Oncology. 17:2183-2192
Aim: To investigate the benefit of chemotherapy among early-stage breast cancer patients with 21-gene recurrence scores of 26–30. Methods: We identified 3754 patients in the Surveillance, Epidemiology, and End Results database. Results: 57.6% of th
Autor:
Erik Van Limbergen, Bülent Polat, Jocelyn Gal, Gilles Houvenaeghel, Jean-Michel Hannoun-Levi, Benjamin Guix, Cristina Gutierrez, Marie-Eve Chand, Vratislav Strnad, Renaud Schiappa, Csaba Polgár, Aurélie Belliere-Calandry, K. Loessl, Daniela Kauer-Domer, Razvan Galalae, David Pasquier, Séverine Racadot, Claire Lemanski, Viktor Smanykó
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 110:452-461
Purpose Second conservative treatment has emerged as an option for patients with a second ipsilateral breast tumor event after conserving surgery and breast irradiation. We aimed to address the lack of evidence regarding second breast event treatment
Autor:
Bianca Lederer, Arndt Hartmann, Hans Ulrich Ulmer, Wolfgang D. Schmitt, Sonia L. Villegas, Jutta Engel, Frank Holms, Andreas Schneeweiss, Bruno Valentin Sinn, Claus Hanusch, Michael Untch, Karsten Weber, Valentina Nekljudova, Marion van Mackelenbergh, Frederik Marmé, Hans Tesch, Clemens Heinrichs, Christian Albig, John Hackmann, Jens Huober, Christian Jackisch, Marion Kiechle, Nicole Pfarr, Wilko Weichert, Mahdi Rezai, Simone Schrodi, Carsten Denkert, Peter A. Fasching, Peter Sinn, Sibylle Loibl
Publikováno v:
European Journal of Cancer. 148:159-170
AIM To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. METHODS We compared
Autor:
Shani Paluch-Shimon, Rachel Michaelson-Cohen, Ariela Tomer, Shunit Armon, Shira Gabizon-Peretz, Naama Srebnik-Moshe, Pnina Mor, Ephrat Levy-Lahad
Publikováno v:
European Journal of Cancer. 148:95-102
Introduction BRCA1/BRCA2 mutation carriers often undergo risk-reducing salpingo-oophorectomy (RRSO) before natural menopause, raising the issue of hormonal replacement treatment (HRT) use. There is conflicting evidence on the effect of HRT on breast